MedTrace Logo

Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects

NCT00295022 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 418

Last updated 2018-09-11

Study results available
· View outcomes & findings →

Summary

To compare the clinical efficacy of levocetirizine 5 mg and montelukast 10 mg on symptoms of seasonal allergic rhinitis occurring in subjects exposed to ragweed pollen in an environmental exposure unit.

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

DRUG

Placebo

* Pharmaceutical form: Over-encapsulated tablet * Route of administration: Oral use

DRUG

Montelukast

* Pharmaceutical form: Over-encapsulated tablet * Concentration: 10 mg * Route of administration: Oral use

DRUG

Levocetirizine

* Pharmaceutical form: Over-encapsulated tablet * Concentration: 5 mg * Route of administration: Oral use

Sponsors & Collaborators

  • UCB S.A. - Pharma Sector

    lead INDUSTRY

Principal Investigators

  • UCB Cares · UCB (+1 844 599 2273)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-29
Primary Completion
2006-10-01
Completion
2006-10-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00295022 on ClinicalTrials.gov